Cosibelimab-ipdl: Revision history

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 February 2025

  • curprev 10:2010:20, 12 February 2025 Nehal Eid talk contribs 6,051 bytes +6,051 Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=programmed death ligand-1 (PD-L1) blocking antibody |indicationType=treatment |indication=It is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. |adverseReactions=The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea,..."
Retrieved from "https://www.wikidoc.org/index.php/Cosibelimab-ipdl"